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Causes and risk factors for death in systemic sclerosis: a study
from the EULAR Scleroderma Trials and Research (EUSTAR)
database
Abstract
OBJECTIVES: To determine the causes and predictors of mortality in systemic sclerosis (SSc).
METHODS: Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria and
prospectively followed in the EULAR Scleroderma Trials and Research (EUSTAR) cohort were
analysed. EUSTAR centres completed a structured questionnaire on cause of death and comorbidities.
Kaplan-Meier and Cox proportional hazards models were used to analyse survival in SSc subgroups and
to identify predictors of mortality.
RESULTS: Questionnaires were obtained on 234 of 284 fatalities. 55% of deaths were attributed
directly to SSc and 41% to non-SSc causes; in 4% the cause of death was not assigned. Of the
SSc-related deaths, 35% were attributed to pulmonary fibrosis, 26% to pulmonary arterial hypertension
(PAH) and 26% to cardiac causes (mainly heart failure and arrhythmias). Among the non-SSc-related
causes, infections (33%) and malignancies (31%) were followed by cardiovascular causes (29%). Of the
non-SSc-related fatalities, 25% died of causes in which SSc-related complications may have participated
(pneumonia, sepsis and gastrointestinal haemorrhage). Independent risk factors for mortality and their
HR were: proteinuria (HR 3.34), the presence of PAH based on echocardiography (HR 2.02), pulmonary
restriction (forced vital capacity below 80% of normal, HR 1.64), dyspnoea above New York Heart
Association class II (HR 1.61), diffusing capacity of the lung (HR 1.20 per 10% decrease), patient age at
onset of Raynaud's phenomenon (HR 1.30 per 10 years) and the modified Rodnan skin score (HR 1.20
per 10 score points).
CONCLUSION: Disease-related causes, in particular pulmonary fibrosis, PAH and cardiac causes,
accounted for the majority of deaths in SSc.
doi: 10.1136/ard.2009.114264
2010
 2010 69: 1809-1815 originally published online June 15,Ann Rheum Dis
 
Anthony J Tyndall, Bettina Bannert, Madelon Vonk, et al.
 
Trials and Research (EUSTAR) database
Sclerodermasclerosis: a study from the EULAR 
Causes and risk factors for death in systemic
 http://ard.bmj.com/content/69/10/1809.full.html
Updated information and services can be found at: 
These include:
References
 http://ard.bmj.com/content/69/10/1809.full.html#related-urls
Article cited in: 
 
 http://ard.bmj.com/content/69/10/1809.full.html#ref-list-1
This article cites 29 articles, 16 of which can be accessed free at:
service
Email alerting
box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in the
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://journals.bmj.com/cgi/ep
To subscribe to BMJ go to:
 group.bmj.com on January 31, 2011 - Published by ard.bmj.comDownloaded from 
Extended report
Ann Rheum Dis 2010;69:1809–1815. doi:10.1136/ard.2009.114264 1809
ABSTRACT
Objectives To determine the causes and predictors of 
mortality in systemic sclerosis (SSc).
Methods Patients with SSc (n=5860) fulfi lling 
the American College of Rheumatology criteria and 
prospectively followed in the EULAR Scleroderma Trials 
and Research (EUSTAR) cohort were analysed. EUSTAR 
centres completed a structured questionnaire on cause 
of death and comorbidities. Kaplan–Meier and Cox 
proportional hazards models were used to analyse survival 
in SSc subgroups and to identify predictors of mortality.
Results Questionnaires were obtained on 234 of 284 
fatalities. 55% of deaths were attributed directly to SSc 
and 41% to non-SSc causes; in 4% the cause of death 
was not assigned. Of the SSc-related deaths, 35% were 
attributed to pulmonary fi brosis, 26% to pulmonary 
arterial hypertension (PAH) and 26% to cardiac causes 
(mainly heart failure and arrhythmias). Among the non-
SSc-related causes, infections (33%) and malignancies 
(31%) were followed by cardiovascular causes (29%). 
Of the non-SSc-related fatalities, 25% died of causes in 
which SSc-related complications may have participated 
(pneumonia, sepsis and gastrointestinal haemorrhage). 
Independent risk factors for mortality and their HR 
were: proteinuria (HR 3.34), the presence of PAH based 
on echocardiography (HR 2.02), pulmonary restriction 
(forced vital capacity below 80% of normal, HR 1.64), 
dyspnoea above New York Heart Association class II 
(HR 1.61), diffusing capacity of the lung (HR 1.20 per 
10% decrease), patient age at onset of Raynaud’s 
phenomenon (HR 1.30 per 10 years) and the modifi ed 
Rodnan skin score (HR 1.20 per 10 score points).
Conclusion Disease-related causes, in particular 
pulmonary fi brosis, PAH and cardiac causes, accounted 
for the majority of deaths in SSc.
Systemic sclerosis (SSc) is a multisystem disease with 
vascular, infl ammatory and fi brotic components. 
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The mortality of SSc is high.1–3 Several studies have 
suggested that the cause of death has changed over 
time, possibly because the natural history of SSc 
complications such as renal crisis and pulmonary 
arterial hypertension (PAH) are altered by pharma-
cological prevention and treatment.4 5 In addition to 
the temporal changes in the causes of SSc mortal-
ity, regional and centre-specifi c prevalences of organ 
involvement and survival have been noted.2 6
We therefore aimed to (1) obtain information on 
the cause of death, (2) the prevalence of comorbidi-
ties in those that died and (3) to identify indepen-
dent predictors of death in SSc in the current era. 
In order to diminish regional bias, we assessed sur-
vival in the multinational EULAR Scleroderma Trial 
and Research (EUSTAR) cohort.7 The data gained 
are important for the appropriate planning of clini-
cal trials because high-risk interventions may only 
be justifi ed in patients with a high likelihood of an 
adverse outcome in the absence of treatment.
METHODS
Data collection
The EUSTAR database was inaugurated in June 
2004 and represents a multinational, prospective 
and open SSc cohort in which consecutive patients 
with scleroderma are included if they provide 
informed written consent. The structure of the 
minimal essential dataset (MEDS), which is col-
lected in the EUSTAR database has been described 
previously.7 Follow-up visits are documented annu-
ally. SSc cases registered as dead up to April 2008 
were analysed. The EUSTAR database contains a 
domain in which participating centres provide the 
date of death and assess whether the death was 
due to SSc itself, the treatment of SSc, or due to 
non-SSc-related causes.
For the purpose of this study, centres registering 
an SSc fatality were invited to fi ll out a standardised 
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questionnaire. In the fi rst section of this form, centres had to 
choose the single primary cause of death from a set of predefi ned 
categories including cardiovascular, respiratory, renal, infec-
tious, neoplastic, gastrointestinal, suicidal and other causes. The 
centre was required to distinguish between the most important 
(primary) clinical problem and inevitable secondary terminal 
events. As an example, the centre was instructed to document 
pneumonia or PAH, rather than cardiac arrest.
In the second part of the questionnaire, the centres had to 
document any clinically signifi cant comorbidity. In this part of 
the form, clinicians had an unlimited choice from a similar set of 
predefi ned comorbidities. Space for explanatory comments was 
also provided.
Three experienced rheumatologists evaluated the forms for 
completeness and plausibility. Disagreement was solved by con-
sensus after queries with the centre.
Data analysis
Causes of death were analysed using standard descriptive sta-
tistics. Categorical variables were compared using χ2 statistics. 
MEDS data were used to determine risk factors for mortality. 
For this purpose, the survival data of SSc patients who had at 
least one annual visit after their inclusion in EUSTAR were 
analysed. Survival distribution functions in Kaplan–Meier plots 
were generated from MEDS parameters. MEDS parameters 
found to affect survival signifi cantly in a fi rst univariate analysis 
were then entered in a multivariate Cox proportional hazards 
model with a stepwise selection procedure in order to calculate 
independent predictors of mortality. The statistical analysis was 
performed with SAS version 9.2.
RESULTS
A total of 5860 patients diagnosed with SSc according to the 
American College of Rheumatology criteria had been enrolled 
in the EUSTAR cohort.8 One hundred and forty-fi ve centres 
in 28 European and six non-European countries had partici-
pated. Two hundred and eighty-four patients (5.2%) from 64 
centres in 29 countries died after enrolment. Two hundred 
and twenty-nine deceased patients (80.6%) were women. The 
mean age at recruitment was 57 years. The total number of 
person-years of follow-up was 5268 years. The mean duration 
of follow-up was 0.9 years per person. Dead patients had been 
followed in the cohort for a mean period of 1.3 years (SD 1.1) 
after inclusion. The mean age at death was 61.7 years (SD 13.3 
years). The annual mortality was 68 per 1000 person-years of 
follow-up.
Of the 284 deceased patients, we received 234 (82%) com-
pleted questionnaires from 45 centres in 19 European and 
four non-European countries. Fifty questionnaires were not 
returned; although these cases were excluded from the ‘causes 
of death analysis’, they were included in the calculation of 
predictors of death based on the MEDS data. When we com-
pared the cases with documented cause of death with those 
without returned cause of death questionnaires, we did not 
fi nd a signifi cant difference of age at death, disease duration, 
gender, antibody status, proteinuria, modifi ed Rodnan skin 
score (mRSS), diffusing capacity of the lung for carbon mon-
oxide (DLCO), dyspnoea, the presence of PAH and pulmonary 
restriction (p>0.05 for all parameters). This fi nding supports 
the notion that the course of SSc was not more or less severe 
between the 234 patients in whom a questionnaire was avail-
able, compared with the 50 patients for whom we had no 
cause of death data.
Among the total of 284 dead patients, 54.6% had diffuse cuta-
neous (dc) SSc and 40.5% had limited cutaneous (lc) SSc, com-
pared with 34.7% with dcSSc and 60.1% with lcSSc among the 
patients who were alive at the last follow-up (p<0.001). Among 
the 284 patients who died, the median SSc disease duration as 
estimated from the onset of Raynaud’s phenomenon until death 
was 7.1 years for patients with dcSSc and 15.0 years for lcSSc; 
47.9% of the patients who had died had serum autoantibodies 
against topoisomerase I (Scl70), and 20.8% had anticentromere 
antibodies (ACA). For comparison, these autoantibody frequen-
cies among the survivors were 35.3% and 32.9%, respectively 
(p<0.001 for both). The median mRSS of the patients who died 
was 13, compared with the mRSS of nine among the survivors 
(p<0.001).
Primary causes of death
The majority of deaths (55%) were attributed to SSc directly 
(table 1).
Nineteen per cent of all SSc fatalities had died of pulmo-
nary fi brosis and 14% of PAH. SSc-related myocardial causes 
(14%) were to a large part attributed to arrhythmia (6% of total 
deaths). Renal causes accounted for the death of 10 patients 
(4%), all due to renal crisis. Renal crisis was fatal in 16% of all 
patients experiencing renal crisis. Seven patients (3%) died of 
gastrointestinal-related causes.
In those having died from arrhythmia, no cardiomyopathy 
was noted. However, 47% of arrhythmia cases did have a 
history of PAH (71% of which was secondary to pulmonary 
fi brosis). Twenty-seven per cent had pulmonary fi brosis with-
out PAH.
One of the fi ve patients dying with right heart failure had 
borderline PAH. Two patients with right heart failure had pul-
monary fi brosis without PAH and one patient had diastolic dys-
function. In these cases, death due to right heart failure was not 
considered as secondary to other factors. Unfortunately, neither 
biopsy nor autopsy data were available to confi rm suspected 
cardiomyopathy.
Non-SSc-related causes accounted for 41% of all deaths. 
Infectious (13% of all deaths), neoplastic (13%) and cardiovas-
cular causes (12%) scored almost equally. Pneumonia predomi-
nated among the infections (17 pneumonia cases among 31 
fatalities from infections). Among the malignancies, non-small 
cell lung cancer was clearly most prevalent (11 cases among 30 
malignancies).
Comorbidities
The non-SSc-related deaths documented in the second part of 
the questionnaire were then analysed for SSc-related comorbidi-
ties. At least 24 of the 96 patients (25%) who died of a non-SSc-
related cause had SSc-related comorbidities that were judged to 
have signifi cantly contributed to the non-SSc-related mortality 
(table 2).
Thirteen of the 17 patients who died from pneumonia also 
had considerable SSc-related risk factors, as judged by the pres-
ence of oesophageal refl ux with or without documented aspi-
ration, or signifi cant immobility. Septicaemia in the context of 
chronic ulcers, immobility and contractures was also frequent 
(six of 14 fatalities due to septicaemia).
Nine of the 14 lung cancer deaths had concomitant pulmo-
nary fi brosis. Pulmonary fi brosis was not, however, signifi -
cantly more frequent in the lung cancer cases (64%) than in the 
total EUSTAR cohort (2363 patients with lung fi brosis, 40.3%, 
p=0.12).
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for age 30 to <50 years, 2.48 for age 50 to <70 years, 3.80 for age 
>70 years, p<0.001), male gender (HR 1.61, p<0.002), the pres-
ence of Scl70 autoantibodies (compared with ACA, HR 1.59, 
p<0.002) and the duration of SSc (as measured by the onset of 
Raynaud’s phenomenon at study inclusion (HR 1.47, p=0.004). 
At the cardiopulmonary level, the presence of PAH diagnosed 
by echocardiography (HR 2.42, p<0.001), the presence of pul-
monary fi brosis on chest x-ray (HR 1.71, p<0.001), the fi nding 
of a forced vital capacity (FVC) below 80% of normal (HR 2.24, 
p<0.001), a reduced DLCO (HR 6.01 for DLCO <40% of nor-
mal, 4.16 for DLCO 40 to <60% of normal, HR 1.71 for DLCO 
60 to <80% of normal p<0.001), a reduced left ventricular ejec-
tion fraction (HR 2.86, p<0.001), a New York Heart Association 
functional class III or IV for dyspnoea (HR 2.32, p<0.001), pal-
pitations (HR 1.30, p<0.048) and arterial hypertension (HR 1.38, 
p=0.007) were all univariately associated with increased mor-
tality. Finally, a history of renal crisis (HR 2.89, p<0.001), the 
presence of proteinuria (HR 3.09, p<0.001), elevated acute phase 
reactants (HR 1.79, p<0.001), elevated creatine kinase (HR 1.73, 
p<0.001) and muscle weakness (HR 1.55, p<0.001) were asso-
ciated with decreased survival. Gastrointestinal manifestations 
in contrast (oesophageal, gastric or intestinal involvement) had 
no signifi cant impact on the risk of dying in univariate analysis 
(p=0.93).
In the multivariate Cox proportional hazards model, inde-
pendent risk factors for increased mortality were the presence 
of proteinuria on urine dipstick analysis, the presence of PAH, 
an impaired pulmonary compliance (FVC <80% of normal), the 
presence of dyspnoea on exertion, a reduced DLCO, an ele-
vated age of SSc onset as estimated by the fi rst manifestation of 
Raynaud’s phenomenon and the mRSS. The magnitude of the 
HR of these independent predictors is shown in table 3.
The Kaplan–Meier survival curves are shown in fi gure 1. 
Of note, SSc subtype, autoantibody status and gender did not 
remain independent ‘predictors’ of subsequent death, nor did 
elevated acute phase reactants, serum creatine kinase measure-
ments and muscle weakness.
Of note, age was not automatically selected into the Cox pro-
portional hazards model. When forcing age as a parameter into 
the model, the other determinants of mortality (PAH, proteinu-
ria, mRSS, DLCO) practically remained unchanged, whereas the 
age at onset of Raynaud’s phenomenon was eliminated. This 
suggests that age at onset of Raynaud’s phenomenon and age 
itself are predictors that are highly correlated but that age at dis-
ease onset is the more important predictor.
DISCUSSION
This study analysed the mortality of SSc patients in the prospec-
tive multinational EUSTAR cohort. The dataset comprised the 
MEDS data and a structured questionnaire.7 The results dem-
onstrate a high prevalence of disease-related causes of death. 
The prevalence of SSc-related causes of mortality is similar, or in 
between the fi gures of other cohorts.3 5 Our fi ndings underscore 
the high prevalence of pulmonary (interstitial lung disease and 
PAH), as well as myocardial causes.9 10
Since the introduction of ACE inhibitors, renal crisis appears 
to have become an increasingly less frequent terminal event.5 
In our cohort, renal crisis accounted for 4% of the deaths, simi-
lar to the recent data from Pittsburgh.5 Except one individual, 
all patients dying from renal crisis were on an ACE inhibitor 
at the time of death (data not shown). Prednisone equivalents 
above 15 mg daily has been implicated in exacerbating sclero-
derma renal crisis, but in our study only one patient was on such 
Predictors of death
A total of 2940 patients had a baseline visit plus at least one 
additional follow-up; these were used to compare survival 
univariately in Kaplan–Meyer curves and to determine HR of 
mortality by multivariate Cox regression modelling. When com-
paring the clinical features between patients with no follow-up 
and those with a follow-up, we found no meaningful difference 
with respect to most key parameters.
The univariate analysis of all MEDS parameters with regard 
to their association with mortality showed that decreased sur-
vival was associated with more extensive skin involvement at 
baseline, as evidenced by the mRSS, in which the HR was 1.55 
for mRSS 10 to less than 20, HR 2.14 for mRSS 20 to less than 
30, and HR 4.31 for mRSS 30–40 (p<0.001), dcSSc subtype (vs 
lcSSc, HR 1.63, p<0.001) and the presence of digital ulcers (HR 
1.61, p<0.001). Furthermore, increased mortality was associated 
with a higher age at the onset of Raynaud’s phenomenon (1.22 
Table 1 Primary causes of death in 234 patients with SSc
 N %
All death cases 234 100
SSc-related death cases 128 55
 Pulmonary 78 33
  Pulmonary fi brosis 45 19
  Isolated PAH 33 14
 Myocardial 33 14
  Arrhythmia 14 6
  Left heart failure 8 3
  Right heart failure 5 2
  Biventricular heart failure 4 2
  Pericarditis (constriction and/or tamponade) 2 1
 Renal 10 4
  Renal crisis 10 4
 Gastrointestinal 7 3
Non-SSc-related death cases 96 41
 Infections 31 13
  Pneumonia 17 7
  Septicaemia 14 6
 Malignancy 30 13
  Non-small cell lung cancer 11 5
  Small cell lung cancer 3 1
  Breast cancer 4 2
  Colorectal cancer 2 1
  Hepatocellular carcinoma 2 1
  Acute myeloid leukaemia 1 <1
  Lymphoma 1 <1
  Renal cell carcinoma 1 <1
  Multiple myeloma 1 <1
  Pancreas carcinoma 1 <1
  Angiosarcoma 1 <1
  Neuroendocrine cancer 1 <1
  Oesophageal cancer 1 <1
 Cardiovascular 28 12
  Myocardial infarction 11 5
  Left heart failure (non-ischaemic) 6 3
  Stroke 6 3
  Pulmonary embolism 4 2
  Arrhythmia (not SSc-related) 1 <1
 Other 7 3
  Gastrointestinal haemorrhage 3 1
  Perforated diverticulitis 1 <1
  Accident 1 <1
  Iatrogenic 1 <1
  Suicide 1 <1
Cause of death unknown 10 4
PAH, pulmonary arterial hypertension; SSc, systemic sclerosis.
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treatment in the 3 months before the onset of renal crisis (data 
not shown).11
Among the non-SSc-related causes, infections, malignancies 
and cardiovascular incidents ranked highest. It should be noted, 
however, that a quarter of the patients with a non-SSc-related 
cause of death also had signifi cant SSc-related comorbidity. If 
these deaths were adjudicated as ‘probably disease related’, the 
disease-related death toll would be as high as 65%.
Interestingly, an association between interstitial lung disease 
and lung cancer, especially non-small cell lung cancer has been 
noted.12–14 Nine of the 14 lung cancer cases in our cohort had pul-
monary fi brosis, but the proportion of pulmonary fi brosis among 
the non-cancer EUSTAR patients did not differ statistically from 
that in our cancer cases. Although our analysis is limited by the 
absence of the smoking history, most lung tumours previously 
noted in patients with SSc were bronchioalveolar carcinomas or 
adenocarcinomas, malignancies that are not necessarily associ-
ated with cigarette smoking.13 Another population-based study 
has not confi rmed an increased risk of lung cancer among SSc 
patients compared with the general population.15
Cardiovascular disease, especially premature atherosclero-
sis, had been implicated as the cause of early death in other 
infl ammatory autoimmune diseases such as rheumatoid arthri-
tis and systemic lupus erythematosus.16 17 In SSc, however, 
an increased prevalence of macroscopic coronary artery or 
cerebrovascular involvement has not been demonstrated.18 19 
In SSc, it rather appears that cardiac microvessel involvement 
results in patchy replacement fi brosis, congestive cardiac fail-
ure and tachyarrhythmia rather than clinically overt myocar-
dial infarction.20
Determining the exact cause of death poses problems. Patients 
may die at home away from diagnostic facilities, a circumstance 
that may cause disparities between death certifi cates and adju-
dicated expert judgement.21 Access to detailed clinical records 
has an infl uence on death certifi cates, as autopsies are only 
performed in the minority of cases.22 23 Comorbidities may be 
underestimated in their causal association and impact on mor-
tality.3 24 Study results may also be biased by the coding of death 
certifi cates, rather than true disease patterns.25 Our study is also 
subject to these limitations. Although centres are asked to include 
SSc patients in EUSTAR consecutively and regardless of disease 
severity, we can not fully exclude the possibility that milder 
cases not under a rheumatologist’s care may have been excluded. 
It is also unlikely that a high proportion of severe patients in the 
centres’ care had died before entry into the EUSTAR registry, 
but it should be noted that in such cohorts, ‘dropouts’ at annual 
12-month census could be due to death or ‘lost to follow-up’, 
leading to over-representation of survivors. Although such left-
censorship bias is diffi cult to rule out, we found that the mean 
follow-up of fatalities was longer than the follow-up of the sur-
vivors. Nevertheless, annual mortality must be interpreted with 
caution, whereas the predictors of mortality are relatively robust. 
Finally, there may a centre-related patient selection bias, but the 
inclusion of a large number of centres contributing to MEDS is 
likely to reduce this potential confounder considerably.6
We evaluated independent predictors of mortality in terms of 
HR. Proteinuria was the strongest predictor of death. Similar to 
the fi nding of others1 proteinuria may be a marker of endothelial 
dysfunction. An independent infl uence of skin involvement on 
survival was previously determined using Cox regression analy-
sis. dcSSc conferred a higher adverse risk compared with lcSSc 
but in our study skin involvement appeared to be better adjusted 
for by the more continuous mRSS model.3 24 26
Previous studies have delineated the importance of internal 
organ involvement.1 2 4 27 Our study also underlines the signifi cant 
adverse effects of pulmonary restriction, reduced DLCO and PAH 
on mortality. The fi nding of PAH and pulmonary restriction as 
independent risk factors for mortality is also consistent with fi nd-
ings indicating a reduced survival in patients with interstitial lung-
associated PAH compared with those with PAH alone.1 2 27–29
The presence of anti-topoisomerase I serum antibodies was 
previously found to be an independent risk factor for mortality.2 26 
Table 2 SSc-related co-morbidities among patients deemed to have died from causes unrelated to SSc 
(sepsis, pneumonia and gastrointestinal haemorrhage)
Cause of death
No signifi cant SSc 
comorbidity (N)
Signifi cant SSc 
comorbidity (N) Type of SSc-associated comorbidity or disease entity
Pneumonia 4 13 Oesophageal refl ux (8) with aspiration (5)
Bedridden patients (5)
Septicaemia 6  8 Gangrene, leg ulcers and decubitus (6)
Surgery for Barrett’s oesophagus (1)
Addison’s crisis due to prednisone withdrawal (1)
Gastrointestinal haemorrhage 1  2 Oesophageal haemorrhage due to primary biliary cirrhosis
SSc, systemic sclerosis.
Table 3 Independent risk factors for reduced survival in SSc patients by Cox regression modelling
HR, 95% CI
Risk factor p Value HR Lower Upper χ2
Presence of proteinuria (‘+’ or more on urine dipstick) <0.001 3.343 2.114 5.286 49.6
PAH <0.001 2.018 1.440 2.827 63.1
Pulmonary restriction (FVC <80% of normal) 0.014 1.644 1.108 2.438 10.3
Presence of dyspnoea (NYHA functional class III or IV) 0.012 1.608 1.111 2.328 4.8
Age at onset of Raynaud’s phenomenon (per 10 years) <0.001 1.295 1.158 1.448 21.8
DLCO (per 10% decrease of normal) <0.001 1.203 1.118 1.295 33.9
mRSS (per 10 score points) 0.024 1.198 1.025 1.402 4.3
Risk factors are ranked by HR. χ2 Scores indicate to what extent each factor helps improve prediction of mortality.
DLCO, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; mRSS, modifi ed Rodnan skin score; NYHA, New 
York Heart Association; PAH, pulmonary arterial hypertension diagnosed by echocardiography.
14_annrheumdis114264.indd   1812 9/17/2010   1:02:14 PM
 group.bmj.com on January 31, 2011 - Published by ard.bmj.comDownloaded from 
Extended report
Ann Rheum Dis 2010;69:1809–1815. doi:10.1136/ard.2009.114264 1813
Figure 1 Kaplan–Meier graphs for systemic sclerosis (SSc) survival on the basis of the follow-up data of 2940 patients of whom 384 had died. SSc 
mortality is plotted according to the presence or absence of proteinuria on dipstick analysis (A), pulmonary arterial hypertension (PAH) diagnosed by 
echocardiography (B), pulmonary restriction as indicated by a forced vital capacity (FVC) below 80% of normal (C), dyspnoea above the functional 
class II of the New York Heart Association (D), the patient’s age at the onset of Raynaud’s phenomenon (E), the diffusing capacity of the lung for 
carbon monoxide (DLCO) in percentage of normal (F) and the modifi ed Rodnan skin score (mRSS). p Values refer to univariate comparisons (A–D) or 
tests for trend (E–G).
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